11:47 AM EST - Immunovaccine Inc. : Announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax(TM)-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes. Immunovaccine Inc.
shares T.IMV are trading down $0.01 at $0.62.
